2Année·

News: $IBRX (-6,11 %) US FDA approves bladder cancer therapy from ImmunityBio!

Very positive for the rest of the pipeline ... lets go!

11 Commentaires

PaulPaulsonle@PaulPaulsonle

2Année

I opened a mini position, I'm very excited

•

JoSt.@JoSto2001

8Mo

@PaulPaulsonle Hopefully held ;)

•

PaulPaulsonle@PaulPaulsonle

8Mo

@JoSto2001 Jess😂😂

••

Fuchs89@mrfux

2Année

a milestone in cancer therapy. I have been invested since 2021 and will hold for a long time

•

Chris Lee@Vestin

2Année

@nit I am also invested and very confident. Great company and only at the beginning.

•

TrendingRobin@TrendingRobin

2Année

Also invested since 2021 and looking forward to the development

•

Hugo_Offiziell@_Hugo_

2Année

You did everything right 👍🏻. Once again, I hesitated too long 🙄

••

PaulPaulsonle@PaulPaulsonle

2Année

Do any of you know why they have already risen 9% in pre-market trading today?
Greetings

••

Fuchs89@mrfux

2Année

@PaulPaulsonle
https://finance.yahoo.com/news/immunitybio-executive-chairman-dr-patrick-120000920.html

Patrick Soon-Shiong will present the implications and results of N-803 (ANKTIVA) at the annual meeting of the AUA (American Urological Association).

••

PaulPaulsonle@PaulPaulsonle

2Année

Thank you very much👌👌👌👌
I'm currently considering whether I should increase my position by a lot before the stock market opens in America😅
Do you think that's a good idea?

••

Fuchs89@mrfux

2Année

@PaulPaulsonle I can't tell you, as I don't have a crystal ball ^^ With a market cap of over 5 billion, a lot of future performance is of course already priced in. Personally, I think that risk/reward is very attractive in both the short and long term. However, you should not rely on other opinions, but do your own research and adjust your position according to your risk management.
(not investment advice)

••